Developer docs
API playgroundTry for free, no card

Search company profiles

Cleveland Diagnostics

Full company profile

uuid0000h4z

Namestring
Cleveland Diagnostics
Legal namestring
Cleveland Diagnostics, Inc.
Websiteurl
clevelanddx.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Cleveland Diagnostics, Inc. is a Cleveland, Ohio-based precision oncology diagnostics company founded in November 2013 as a spinout of Cleveland Clinic Innovations. The company develops a novel class of simple, affordable blood tests for cancer detection and risk assessment built on its proprietary IsoClear platform, which measures structural differences in proteins to determine whether biomarkers originated in cancer cells rather than relying on protein concentration alone. Its lead commercial product, IsoPSA, is a blood-based prostate cancer diagnostic that aids biopsy decision-making for men over 50 with elevated PSA levels and has been clinically validated to reduce unnecessary prostate biopsies by up to 55% with specificity 2-3x that of traditional PSA tests.

The company operates a dual-distribution model. It runs a CLIA-certified, CAP-accredited, SOC 2 Type II audited laboratory in Cleveland, Ohio, offering the IsoPSA test as both a laboratory-developed test (LDT) since July 2020 and an FDA-approved IVD assay since December 2025. It also distributes through enterprise partnerships, most notably a channel agreement with Quest Diagnostics (announced February 2023) for nationwide patient access and a digital-pathology workflow integration with Lumea (announced December 2025). Reimbursement is enabled by Medicare Local Coverage Determination and an assigned CPT-PLA code (October 2022), with NCCN Guideline inclusion (2022) supporting standard-of-care adoption.

Cleveland Diagnostics has raised approximately $112 million across multiple financing rounds (most recently $75M in January 2024 led by Novo Holdings and a $14.42M SEC Form D filing in October 2025), with Novo Holdings, Lyfe Capital, and Cleveland Clinic Innovations represented on the board. The company holds ISO 13485:2016 certification (May 2026), FDA Breakthrough Device Designation (2019), and operates state licenses in California, Maryland, Pennsylvania, Rhode Island, and New York. Its leadership bench was substantially refreshed in 2024-2026 with the appointments of CEO Michael Iskra, Chairman Jack Kenny, and new board directors Dara Grantham Wright and Rich Ramko, all signaling a transition from clinical-validation-stage to commercial-scale-stage operations.

Short descriptiontext

Cleveland Diagnostics is a Cleveland, Ohio-based precision oncology company developing blood-based cancer diagnostics on its proprietary IsoClear protein-structure platform. Its lead product, IsoPSA, is an FDA-approved prostate cancer test that helps urologists avoid unnecessary biopsies in men with elevated PSA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCleveland, United States
HQ citystring
Cleveland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer diagnostics, prostate cancer testing, blood-based biomarkers, protein structure analysis, clinical laboratory testing
Industry3 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Cancer Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Laboratory Testing Services
TypeProfessional Services
Description

Revenue from providing IsoPSA testing services through CLIA-certified laboratories. The test is offered as both a laboratory developed test (LDT) and FDA-approved IVD assay following December 2025 FDA approval.

biospace.com
2Diagnostic Assay Commercialization
TypeOne Time License
Description

Revenue from commercialization of FDA-approved IsoPSA IVD Assay for use in clinical settings, with Medicare coverage determination and CPT-PLA code assignment supporting reimbursement.

biospace.com
3Partnership Licensing
TypeLicensing Royalties
Description

Strategic partnerships with Quest Diagnostics and other healthcare providers expand access to testing, generating revenue through service agreements and expanded market reach.

clevelanddx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Medicare Reimbursement
ModelOtherBilling cadencePay-as-you-go
Notes

Favorable Medicare local coverage determination and assignment of CPT-PLA code for IsoPSA® announced October 2022

clevelanddx.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1IsoPSA
Description

Blood-based prostate cancer test that reduces unnecessary biopsies by up to 55%, with sensitivity and specificity 2-3 times that of traditional PSA tests.

clevelanddx.com
+1 more record
Core offering1 text field

Cleveland Diagnostics develops and commercializes blood-based cancer diagnostic tests built on its proprietary IsoClear platform, which measures structural differences in proteins to determine whether biomarkers originated in cancer cells. Its flagship commercial product, IsoPSA, is a blood-based prostate cancer test offered as both a CLIA-certified laboratory developed test (LDT) and an FDA-approved IVD assay (December 2025) for biopsy decision-making in men over 50 with elevated PSA levels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduces unnecessary prostate biopsies by up to 55%
+1 more record
Product overview1 text field

Cleveland Diagnostics offers a novel class of simple blood tests for cancer detection and risk assessment, built on its proprietary IsoClear platform. The company's first commercial product is IsoPSA, a blood-based prostate cancer test that reduces unnecessary biopsies by measuring structural changes in protein biomarkers. The IsoClear platform serves as the foundational technology enabling the IsoPSA test and supporting expansion into additional cancer indications including thyroid, lung, and multi-cancer diagnostics. The company operates as a commercial-stage precision oncology company with both laboratory-developed test (LDT) and FDA-approved IVD versions of IsoPSA.

Product and service2 records
1IsoPSA (Laboratory Developed Test)
CategoryClinical Laboratory Diagnostic Test
Description

Blood-based prostate cancer test measuring structural differences in protein biomarkers to distinguish aggressive cancer from benign conditions, reducing unnecessary prostate biopsies by up to 55%. Performed in CLIA-certified high-complexity laboratories; intended for men over 50 with elevated PSA levels.

2IsoPSA IVD Assay
CategoryIn Vitro Diagnostic (IVD) Assay
Description

FDA-approved (December 2025) in vitro diagnostic version of IsoPSA that aids in decision-making for prostate biopsies in men over 50 with elevated PSA levels; supports Medicare reimbursement via an assigned CPT-PLA code and inclusion in NCCN Guidelines for Prostate Cancer Early Detection.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-17
Description

Collaboration to integrate IsoPSA prostate cancer blood test into Lumea's digital pathology platform, simplifying access for urologists and enhancing prostate cancer risk assessment. The integration aims to improve clinical workflows and diagnostic accuracy.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-02-13
Description

Strategic agreement to expand patient access to IsoPSA prostate cancer testing through Quest Diagnostics' extensive laboratory network, enabling broader geographic reach and increased testing availability for patients and physicians.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-11-28
Description

Strategic collaboration announced in November 2017 to develop and commercialize new prostate cancer tests, combining Genomic Health's genomic testing expertise with Cleveland Diagnostics' IsoPSA technology platform.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

OPKO Health markets the 4Kscore test, a blood-based prostate cancer diagnostic that helps determine the need for biopsy. It directly competes with IsoPSA in the same clinical use case (pre-biopsy risk stratification for men with elevated PSA) and serves the same urology customer base.

TypeDirect peer
Description

MDxHealth commercializes SelectMDx, a urine-based molecular test for prostate cancer risk assessment prior to biopsy. It is a direct competitor in the prostate cancer diagnostics space, serving the same urologist decision-maker and addressing the same biopsy-avoidance value proposition.

3Beckman Coulter (Danaher)
TypeBroad incumbent
Description

Beckman Coulter offers the Prostate Health Index (PHI), an established blood-based prostate cancer diagnostic with broad installed-base reimbursement. As a large diagnostics incumbent within Danaher, it competes head-to-head with IsoPSA in the same clinical workflow.

TypeBroad incumbent
Description

Exact Sciences is a commercial-stage cancer diagnostics company (Cologuard, Oncotype DX) with a large sales force and proven urology/oncology channel relationships. It is comparable as a scaled cancer diagnostics commercializer pursuing similar customer segments.

TypeBroad incumbent
Description

Guardant Health is a leading liquid biopsy / oncology diagnostics company with FDA-approved tests and large-scale commercial operations. It is comparable as a precision oncology diagnostics peer pursuing blood-based cancer detection and monitoring.

TypeEmerging player
Description

Veracyte is a genomic diagnostics company with urology and oncology franchises (including the Decipher Prostate genomic classifier). It is comparable as a cancer diagnostics peer with overlapping urology customer targets and a portfolio expansion strategy.

TypeBroad incumbent
Description

NeoGenomics is a specialty oncology testing laboratory offering a broad menu of cancer diagnostics. It is comparable as a clinical laboratory operator serving oncologists and urologists with proprietary and third-party cancer tests.

8GRAIL
TypeEmerging player
Description

GRAIL developed the Galleri multi-cancer early-detection blood test, pursuing a blood-based oncology diagnostics model at larger scale. It is comparable as a blood-based cancer detection peer, although operating in a broader (multi-cancer) indication space than IsoPSA.

TypeBroad incumbent
Description

Bio-Techne is a life sciences tools and diagnostics company with proprietary protein-based assay technologies. It is comparable as a diagnostics player leveraging protein biomarker science, with overlapping R&D capabilities in protein analytics.

TypeBroad incumbent
Description

Hologic is a large diagnostics and medical device company with established women's health and emerging oncology diagnostics portfolios. It is comparable as a scaled diagnostics commercializer with regulatory, manufacturing, and sales infrastructure relevant to commercial-stage oncology diagnostics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cleveland Diagnostics

Cancer Diagnosticsclevelanddx.com

Cleveland Diagnostics is a Cleveland, Ohio-based precision oncology company developing blood-based cancer diagnostics on its proprietary IsoClear protein-structure platform. Its lead product, IsoPSA, is an FDA-approved prostate cancer test that helps urologists avoid unnecessary biopsies in men with elevated PSA.

What Cleveland Diagnostics does

Cleveland Diagnostics, Inc. is a Cleveland, Ohio-based precision oncology diagnostics company founded in November 2013 as a spinout of Cleveland Clinic Innovations. The company develops a novel class of simple, affordable blood tests for cancer detection and risk assessment built on its proprietary IsoClear platform, which measures structural differences in proteins to determine whether biomarkers originated in cancer cells rather than relying on protein concentration alone. Its lead commercial product, IsoPSA, is a blood-based prostate cancer diagnostic that aids biopsy decision-making for men over 50 with elevated PSA levels and has been clinically validated to reduce unnecessary prostate biopsies by up to 55% with specificity 2-3x that of traditional PSA tests.

The company operates a dual-distribution model. It runs a CLIA-certified, CAP-accredited, SOC 2 Type II audited laboratory in Cleveland, Ohio, offering the IsoPSA test as both a laboratory-developed test (LDT) since July 2020 and an FDA-approved IVD assay since December 2025. It also distributes through enterprise partnerships, most notably a channel agreement with Quest Diagnostics (announced February 2023) for nationwide patient access and a digital-pathology workflow integration with Lumea (announced December 2025). Reimbursement is enabled by Medicare Local Coverage Determination and an assigned CPT-PLA code (October 2022), with NCCN Guideline inclusion (2022) supporting standard-of-care adoption.

Cleveland Diagnostics has raised approximately $112 million across multiple financing rounds (most recently $75M in January 2024 led by Novo Holdings and a $14.42M SEC Form D filing in October 2025), with Novo Holdings, Lyfe Capital, and Cleveland Clinic Innovations represented on the board. The company holds ISO 13485:2016 certification (May 2026), FDA Breakthrough Device Designation (2019), and operates state licenses in California, Maryland, Pennsylvania, Rhode Island, and New York. Its leadership bench was substantially refreshed in 2024-2026 with the appointments of CEO Michael Iskra, Chairman Jack Kenny, and new board directors Dara Grantham Wright and Rich Ramko, all signaling a transition from clinical-validation-stage to commercial-scale-stage operations.

Cleveland Diagnostics firmographics

Firmographics
Name
Cleveland Diagnostics
Legal name
Cleveland Diagnostics, Inc.
Website
https://clevelanddx.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
Cleveland Diagnostics is a Cleveland, Ohio-based precision oncology company developing blood-based cancer diagnostics on its proprietary IsoClear protein-structure platform. Its lead product, IsoPSA, is an FDA-approved prostate cancer test that helps urologists avoid unnecessary biopsies in men with elevated PSA.
Ownership category
akta.pro rank

Cleveland Diagnostics industry classification

Industry
Product category
Cancer Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Cancer diagnostics
  • Prostate cancer testing
  • Blood-based biomarkers
  • Protein structure analysis
  • Clinical laboratory testing

Where Cleveland Diagnostics is headquartered

Location

Headquarters

HQ city
Cleveland
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cleveland Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Laboratory Testing Services: Revenue from providing IsoPSA testing services through CLIA-certified laboratories. The test is offered as both a laboratory developed test (LDT) and FDA-approved IVD assay following December 2025 FDA approval.
  2. Diagnostic Assay Commercialization: Revenue from commercialization of FDA-approved IsoPSA IVD Assay for use in clinical settings, with Medicare coverage determination and CPT-PLA code assignment supporting reimbursement.
  3. Partnership Licensing: Strategic partnerships with Quest Diagnostics and other healthcare providers expand access to testing, generating revenue through service agreements and expanded market reach.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goMedicare Reimbursement

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Cleveland Diagnostics product offering

Product offering

Core offering

Cleveland Diagnostics develops and commercializes blood-based cancer diagnostic tests built on its proprietary IsoClear platform, which measures structural differences in proteins to determine whether biomarkers originated in cancer cells. Its flagship commercial product, IsoPSA, is a blood-based prostate cancer test offered as both a CLIA-certified laboratory developed test (LDT) and an FDA-approved IVD assay (December 2025) for biopsy decision-making in men over 50 with elevated PSA levels.

Product overview

Cleveland Diagnostics offers a novel class of simple blood tests for cancer detection and risk assessment, built on its proprietary IsoClear platform. The company's first commercial product is IsoPSA, a blood-based prostate cancer test that reduces unnecessary biopsies by measuring structural changes in protein biomarkers. The IsoClear platform serves as the foundational technology enabling the IsoPSA test and supporting expansion into additional cancer indications including thyroid, lung, and multi-cancer diagnostics. The company operates as a commercial-stage precision oncology company with both laboratory-developed test (LDT) and FDA-approved IVD versions of IsoPSA.

Differentiator

Problem solved

Functional benefit

Brands

  • IsoPSA: Blood-based prostate cancer test that reduces unnecessary biopsies by up to 55%, with sensitivity and specificity 2-3 times that of traditional PSA tests.
  • IsoClear

Products and services

  • IsoPSA (Laboratory Developed Test) Blood-based prostate cancer test measuring structural differences in protein biomarkers to distinguish aggressive cancer from benign conditions, reducing unnecessary prostate biopsies by up to 55%. Performed in CLIA-certified high-complexity laboratories; intended for men over 50 with elevated PSA levels.
  • IsoPSA IVD Assay FDA-approved (December 2025) in vitro diagnostic version of IsoPSA that aids in decision-making for prostate biopsies in men over 50 with elevated PSA levels; supports Medicare reimbursement via an assigned CPT-PLA code and inclusion in NCCN Guidelines for Prostate Cancer Early Detection.

Quantifiable outcome

  • Reduces unnecessary prostate biopsies by up to 55%
  • +1 more outcomes

Companies that use Cleveland Diagnostics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Cleveland Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cleveland Diagnostics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • LumeacoreTechnology or Integration · 17 December 2025Collaboration to integrate IsoPSA prostate cancer blood test into Lumea's digital pathology platform, simplifying access for urologists and enhancing prostate cancer risk assessment. The integration aims to improve clinical workflows and diagnostic accuracy.
  • Quest DiagnosticscoreChannel Partner/ Reseller/ Distributor · 13 February 2023Strategic agreement to expand patient access to IsoPSA prostate cancer testing through Quest Diagnostics' extensive laboratory network, enabling broader geographic reach and increased testing availability for patients and physicians.
  • Genomic HealthminorStrategic or Co-development Partner · 28 November 2017Strategic collaboration announced in November 2017 to develop and commercialize new prostate cancer tests, combining Genomic Health's genomic testing expertise with Cleveland Diagnostics' IsoPSA technology platform.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Cleveland Diagnostics competitors and assessment

Company assessment

Direct peers

  • OPKO Health: OPKO Health markets the 4Kscore test, a blood-based prostate cancer diagnostic that helps determine the need for biopsy. It directly competes with IsoPSA in the same clinical use case (pre-biopsy risk stratification for men with elevated PSA) and serves the same urology customer base.
  • MDxHealth: MDxHealth commercializes SelectMDx, a urine-based molecular test for prostate cancer risk assessment prior to biopsy. It is a direct competitor in the prostate cancer diagnostics space, serving the same urologist decision-maker and addressing the same biopsy-avoidance value proposition.

Broad incumbents

  • Beckman Coulter (Danaher): Beckman Coulter offers the Prostate Health Index (PHI), an established blood-based prostate cancer diagnostic with broad installed-base reimbursement. As a large diagnostics incumbent within Danaher, it competes head-to-head with IsoPSA in the same clinical workflow.
  • Exact Sciences: Exact Sciences is a commercial-stage cancer diagnostics company (Cologuard, Oncotype DX) with a large sales force and proven urology/oncology channel relationships. It is comparable as a scaled cancer diagnostics commercializer pursuing similar customer segments.
  • Guardant Health: Guardant Health is a leading liquid biopsy / oncology diagnostics company with FDA-approved tests and large-scale commercial operations. It is comparable as a precision oncology diagnostics peer pursuing blood-based cancer detection and monitoring.
  • NeoGenomics: NeoGenomics is a specialty oncology testing laboratory offering a broad menu of cancer diagnostics. It is comparable as a clinical laboratory operator serving oncologists and urologists with proprietary and third-party cancer tests.
  • Bio-Techne: Bio-Techne is a life sciences tools and diagnostics company with proprietary protein-based assay technologies. It is comparable as a diagnostics player leveraging protein biomarker science, with overlapping R&D capabilities in protein analytics.
  • Hologic: Hologic is a large diagnostics and medical device company with established women's health and emerging oncology diagnostics portfolios. It is comparable as a scaled diagnostics commercializer with regulatory, manufacturing, and sales infrastructure relevant to commercial-stage oncology diagnostics.

Emerging players

  • Veracyte: Veracyte is a genomic diagnostics company with urology and oncology franchises (including the Decipher Prostate genomic classifier). It is comparable as a cancer diagnostics peer with overlapping urology customer targets and a portfolio expansion strategy.
  • GRAIL: GRAIL developed the Galleri multi-cancer early-detection blood test, pursuing a blood-based oncology diagnostics model at larger scale. It is comparable as a blood-based cancer detection peer, although operating in a broader (multi-cancer) indication space than IsoPSA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cleveland Diagnostics social profiles

Digital presence

Cleveland Diagnostics compliance and trust

Trust signal

Compliance4 records

Cleveland Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cleveland Diagnostics leadership team

Management profile

Number of profiles

Profiles12 records

Cleveland Diagnostics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cleveland Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cleveland Diagnostics

What does Cleveland Diagnostics do?

Cleveland Diagnostics develops and commercializes blood-based cancer diagnostic tests built on its proprietary IsoClear platform, which measures structural differences in proteins to determine whether biomarkers originated in cancer cells. Its flagship commercial product, IsoPSA, is a blood-based prostate cancer test offered as both a CLIA-certified laboratory developed test (LDT) and an FDA-approved IVD assay (December 2025) for biopsy decision-making in men over 50 with elevated PSA levels.

Is Cleveland Diagnostics a public or private company?

Cleveland Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cleveland Diagnostics founded?

Cleveland Diagnostics was founded in 2013. It employs 101 to 250 people.

Where is Cleveland Diagnostics based?

Cleveland Diagnostics is headquartered in Cleveland, United States, in the North America region.

How does Cleveland Diagnostics make money?

Three revenue lines are on record. Laboratory Testing Services are the primary driver. The others are diagnostic Assay Commercialization and partnership Licensing.

Who are Cleveland Diagnostics's main competitors?

Direct peers on record are OPKO Health and MDxHealth. Broad incumbents are Beckman Coulter (Danaher), Exact Sciences, Guardant Health, NeoGenomics, Bio-Techne and Hologic. Emerging players are Veracyte and GRAIL.

Does Cleveland Diagnostics have an API?

No public API is recorded for Cleveland Diagnostics.

What industry is Cleveland Diagnostics in?

Cleveland Diagnostics's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MediaPost'PSA on PSA' Turns to Urologists To Spread Prostate Cancer AwarenessCleveland Diagnostics' fourth annual 'PSA on PSA' campaign shifted to a video series featuring urologists, launching Sept. 3 with four 45-minute episodes. The series targets men 50+ to encourage conversations with physicians about prostate cancer screening, citing 333,000 annual diagnoses and 99% treatability when caught early.Business Wire BlogCleveland Diagnostics Launches 4th Annual PSA on PSA Prostate Cancer CampaignCleveland Diagnostics is launching its 4th annual PSA on PSA campaign in September to raise prostate cancer awareness. For every factsheet downloaded, the company donates to ZERO Prostate Cancer, which matches donations to double the impact. The campaign also introduces a new video series on men's health.citybizCleveland Diagnostics Names Valerie Dixon CFO as IsoPSA Commercialization ExpandsCleveland Diagnostics has appointed Valerie Dixon as Chief Financial Officer, bringing 20 years of healthcare investment banking and strategic finance experience, including roles at Morgan Stanley, Flagship Pioneering, J.P. Morgan, Citigroup and Lehman Brothers. The move coincides with the company's expansion of commercialization of its IsoPSA prostate cancer test and development of additional applications for its IsoClear platform.Urology TimesNCCN recommends IsoPSA test for upfront prostate cancer risk assessmentCleveland Diagnostics announced that the National Comprehensive Cancer Network (NCCN) has added its IsoPSA blood test to prostate cancer guidelines for early detection and risk assessment. A clinical validation study involving 734 patients demonstrated that using IsoPSA prior to biopsy reduced provider recommendations for biopsies by 55% while maintaining high accuracy for detecting high-grade cancer.Urology TimesDiagnostics companies enter agreement to expand access to blood-based IsoPSA testCleveland Diagnostics has entered into an agreement with Quest Diagnostics to expand nationwide access to its IsoPSA blood test for prostate cancer detection. The partnership allows patients to provide blood specimens at over 2,100 Quest Diagnostics patient service centers across the United States starting by mid-year. This collaboration leverages Quest’s extensive laboratory infrastructure to make the FDA Breakthrough Therapy designated test more accessible to physicians and patients.Pharmacy TimesFDA Approves IsoPSA Blood Test to Detect Prostate CancerThe FDA has approved the IsoPSA blood test developed by Cleveland Diagnostics, Inc., to help evaluate prostate cancer risk in men aged 50 and older with elevated PSA levels. This approval allows the test to serve as an aid for biopsy decisions, potentially avoiding up to 46% of unnecessary biopsies for high-grade disease compared to traditional methods. The device represents a significant milestone for Cleveland Diagnostics in expanding access to early cancer detection.Urology TimesFDA approves IsoPSA test as aid in the diagnosis of high-grade prostate cancerThe FDA approved the IsoPSA blood-based test on December 1, 2025, to aid in diagnosing high-grade prostate cancer and assisting biopsy decisions for men aged 50 and older with elevated PSA levels. Cleveland Diagnostics announced the approval, which was based on large-scale prospective studies validating the test's ability to distinguish benign PSA elevations from those caused by high-grade cancer. The company aims to expand accessibility and coverage for the test, which is already included in major clinical guidelines.Cancer NetworkFDA Approves Novel Blood-Based Prostate Cancer Test for Elevated PSA LevelsThe FDA has approved the IsoPSA in vitro diagnostic kit, developed by Cleveland Diagnostics, to aid in biopsy decisions for men 50 and older with elevated PSA levels. Clinical data indicates that IsoPSA outperforms standard total and percentage-free PSA tests in detecting high-grade prostate cancer, potentially allowing up to 46% of unnecessary biopsies to be avoided.citybizCleveland Diagnostics Appoints Rich Ramko to Board of DirectorsCleveland Diagnostics, Inc. has appointed Rich Ramko to its Board of Directors, adding a veteran life sciences finance executive with over 30 years of industry experience. Ramko previously served as U.S. Life Sciences & Healthcare Assurance Leader at Ernst & Young and was a member of EY's U.S. and Global Life Sciences Boards. The appointment is intended to support the company's commercialization efforts for its IsoPSA prostate cancer test and expansion of the IsoClear diagnostics platform in the precision oncology sector.Business Wire BlogCleveland Diagnostics Appoints Rich Ramko to Board of DirectorsCleveland Diagnostics, Inc. has appointed Rich Ramko to its Board of Directors to leverage his financial expertise in the life sciences sector. This appointment supports the company's ongoing commercialization of its IsoPSA prostate cancer test and expansion of its IsoClear platform into new therapeutic areas.